Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE

Novavax

Pfizer

Some vaccine makers are better positioned than others.

Which COVID Stocks Are the Best Picks if Coronavirus Variants Spread?

And it could mean at least another $1 billion in revenue for the biotech.

Moderna's Latest Move May be Key to COVID-19 Vaccine Market Dominance

Moderna is developing its COVID-19 vaccine, mRNA-1273, for different patient populations. It is also developing booster vaccine candidates as well as a next-generation COVID vaccine.

Moderna (MRNA) Begins Pediatric Study on COVID-19 Vaccine

They both have plenty to offer investors.

Better COVID Stock: Moderna vs. Pfizer

Moderna, Inc. (MRNA) Presents at Oppenheimer 31st Annual Healthcare Conference Call (Transcript)

Moderna has begun testing its COVID-19 vaccine in young children.  The biotech firm announced Tuesday the first participants in a study of children between 6 months and 12 years old received a doses of the COVID-19 vaccine. Moderna collaborated with the National Institutes of Health and the Biomedical Advanced Research and Development Authority on the study.

Moderna begins testing COVID-19 vaccine in babies and young children

Shares of Moderna rose 6.5% on Tuesday after the drugmaker announced it will begin testing its COVID-19 vaccine on children ages six months to 11 years.  Currently, Moderna and Johnson & Johnson's vaccines are approved only for adults 18 years and older, while vaccine from Pfizer and BioNTech are approved for 16 years and older.

Moderna soars 6% as it begins vaccine testing in babies and children

Moderna Inc. provided a dose of optimism on Tuesday in the fight against the COVID-19 pandemic, as the company said it has started testing a vaccine on young children, just as the U.S. recorded a slight uptick in cases and deaths.

Coronavirus Update: Moderna starts COVID-19 vaccine candidate testing on children, as U.S. cases and deaths tick up

AC Immune

Can-Fite BioPharma Ltd.

Moderna Inc. (NASDAQ: MRNA), AC Immune SA (NASDAQ: ACIU) and Can-Fite BioPharma Ltd. (NYSE: CANF) were among the early biotech movers Tuesday.

Why Can-Fite, Moderna, AC Immune Shares Are Rallying

Moderna stock climbed Tuesday after the company announced it had begun testing its Covid-19 vaccine in children. The company also began a test in December of adolescents.

Moderna Stock Pops As It Begins Covid Vaccine Test In Children

The long-term potential for MRNA stock is weak and doesn't justify its massive valuation, which exceeds $60 billion at this time. The post Investing in Moderna Has Little Upside At This Point appeared first on InvestorPlace.

Investing in Moderna Has Little Upside At This Point

Nikola

Pinduoduo Inc - ADR

Roblox

Starbucks

One of the most common questions traders have about stocks is “Why Is It Moving?” That's why Benzinga created the Why Is It Moving, or WIIM, feature in Benzinga Pro.

Is Now The Time To Buy Stock In Pinduoduo, Starbucks, Roblox, Moderna Or Nikola?

There is no vaccine currently authorized for use in children.

Moderna Begins Testing Covid-19 Vaccine in Children

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces the first participants have been dosed in the Phase 2/3 study of its COVID-19 vaccine candidate in the pediatric population.

Moderna Announces First Participants Dosed in Phase 2/3 Study of COVID-19 Vaccine Candidate in Pediatric Population

Moderna Inc. said Tuesday that it has dosed the first pediatric participants of its KidCOVE Phase 2/3 study of its COVID-19 vaccine candidate, which is being tested for children aged 6 months to less than 12 years. Moderna's stock rose 1.8% in premarket trading.

Moderna starts testing of COVID-19 vaccine candidate in children

Moderna Inc (NASDAQ: MRNA) said Monday that it had commenced testing the next generation of its COVID-19 vaccine. What Happened: The Cambridge, Massachusetts-based company said it had dosed the first volunteers with its vaccine candidate dubbed mRNA-1283.

Moderna Begins Testing Next-Gen COVID-19 Vaccine Candidate: What You Need To Know

Sanofi

Telesis Bio Inc

GlaxoSmithKline

The phase I/II clinical study on Sanofi (SNY)/Translate Bio's (TBIO) COVID-19 vaccine candidate will assess its safety, immune response and reactogenicity.

Sanofi (SNY)/Translate Bio COVID-19 Vaccine in Clinical Stage

CAMBRIDGE, Mass.--(BUSINESS WIRE)--First participants dosed in Phase 1 study evaluating mRNA-1283, Moderna's next generation COVID-19 vaccine.

First Participants Dosed in Phase 1 Study Evaluating mRNA-1283, Moderna's Next Generation COVID-19 Vaccine

Shares of Moderna Inc. gained 1.9% in trading on Monday after the company said it began dosing participants in the Phase 1 clinical trial of its next-generation COVID-19 vaccine candidate. The experimental vaccine is being tested to see if it can be stored in standard refrigeration so that it can be administered in a wider range of locations and regions than the currently authorized two-dose version of the vaccine.

Moderna's stock gains 1.9% as it begins testing COVID-19 vaccine with easier storage requirements

The wisdom of crowds may give us the answer.

The Better Stock for 2021: Moderna or Novavax?

The future is bright, but significant uncertainty remains.

Before You Buy Moderna, Stop and Consider These 3 Things

There's more to the biotech than its coronavirus vaccine.

Here Are the Most Exciting Vaccines in Moderna's Pipeline

AstraZeneca

Was AstraZeneca Smart to Sell Its Moderna Shares?

Applied Molecular Transport

Gritstone Oncology Inc

Here's why these highfliers could have more fuel in the tank.

3 Biotech Stocks That Have Already Rocketed Higher in 2021

Johnson & Johnson

Don't jump to any conclusions based on the different vaccines' advisory committee votes.

News for Moderna Stock (MRNA)